Eterna Therapeutics Stock Analysis
| ERNA Stock | USD 1.29 0.09 6.52% |
Eterna Therapeutics is overvalued with Real Value of 1.24 and Hype Value of 1.27. The main objective of Eterna Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Eterna Therapeutics is worth, separate from its market price. There are two main types of Eterna Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Eterna Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Eterna Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. Eterna Stock Analysis Notes
About 60.0% of the company shares are held by company insiders. The book value of Eterna Therapeutics was currently reported as 0.59. The company recorded a loss per share of 17.76. Eterna Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 12th of June 2025. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Eterna Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Eterna Therapeutics call Sanjeev Luther at 212 582 1199 or check out https://www.ernexatx.com.Eterna Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Eterna Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Eterna Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics may become a speculative penny stock | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 582 K. Net Loss for the year was (44.54 M) with profit before overhead, payroll, taxes, and interest of 548 K. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (15.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: BlackRock Announces Update to BMEZ, BSTZ, and BTX Managed Distribution Plans |
Eterna Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eterna Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Eterna Largest EPS Surprises
Earnings surprises can significantly impact Eterna Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-10-10 | 2019-09-30 | -0.03 | -0.12 | -0.09 | 300 | ||
2022-11-14 | 2022-09-30 | -2.2 | -2.49 | -0.29 | 13 | ||
2019-05-13 | 2019-03-31 | 0.2 | -0.11 | -0.31 | 155 |
Eterna Therapeutics Thematic Classifications
In addition to having Eterna Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | ITInformation technology and IT services | |
 | ComputersUSA Equities from Computers industry as classified by Fama & French |
Eterna Stock Institutional Investors
| Shares | Group One Trading, Lp | 2025-03-31 | 19.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 10.0 | Sbi Securities Co Ltd | 2025-03-31 | 10.0 | Activest Wealth Management | 2025-06-30 | 3.0 | Fmr Inc | 2025-03-31 | 2.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Susquehanna International Group, Llp | 2025-03-31 | 0.0 | Justinvest Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-03-31 | 293.1 K | Ci Private Wealth Llc | 2025-03-31 | 262.9 K |
Eterna Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.9 M.Eterna Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (13.81) | (13.12) | |
| Return On Capital Employed | (6.72) | (6.39) | |
| Return On Assets | (8.45) | (8.03) | |
| Return On Equity | (26.18) | (24.87) |
Management Efficiency
Eterna Therapeutics has return on total asset (ROA) of (0.2719) % which means that it has lost $0.2719 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.6431) %, meaning that it created substantial loss on money invested by shareholders. Eterna Therapeutics' management efficiency ratios could be used to measure how well Eterna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -13.12. The current year's Return On Capital Employed is expected to grow to -6.39. At present, Eterna Therapeutics' Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 12.1 M, whereas Total Assets are forecasted to decline to about 5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.06 | 0.06 | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (3.44) | (3.27) | |
| Price Book Value Ratio | 73.62 | 58.81 | |
| Enterprise Value Multiple | (3.44) | (3.27) | |
| Price Fair Value | 73.62 | 58.81 |
Leadership effectiveness at Eterna Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 12th of September 2025, Eterna Therapeutics shows the Mean Deviation of 3.74, standard deviation of 5.11, and Variance of 26.16. Eterna Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Eterna Therapeutics Price Movement Analysis
The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. Eterna Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Eterna Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Eterna Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eterna Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eterna Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eterna Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eterna Therapeutics Predictive Daily Indicators
Eterna Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eterna Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 1.29 | |||
| Day Typical Price | 1.29 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.09) | |||
| Relative Strength Index | 30.43 |
Eterna Therapeutics Forecast Models
Eterna Therapeutics' time-series forecasting models are one of many Eterna Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eterna Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Eterna Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Eterna Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eterna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Eterna Therapeutics. By using and applying Eterna Stock analysis, traders can create a robust methodology for identifying Eterna entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (76.48) | (80.30) | |
| Operating Profit Margin | (26.93) | (28.28) | |
| Net Loss | (76.53) | (80.35) | |
| Gross Profit Margin | 0.84 | 0.88 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Eterna Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |